Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Alpine Immune Sciences Inc. is most often covered alongside Journavx, which appears in 1 of these 1 story. The 8 average consequence score is above the beat benchmark of 5.9 in the same window.
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Alpine Immune Sciences Inc. is most often covered alongside Journavx, which appears in 1 of these 1 story. The 8 average consequence score is above the beat benchmark of 5.9 in the same window. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. Alpine Immune Sciences Inc. appears in 1 tracked Healthcare story from March 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alpine Immune Sciences Inc.. Shared-story counts are live from our verified record — not editorial picks.
Potential Approval
Estimated decision date if the FDA grants a 6-month priority review.
FDA Filing Deadline
Target date for completing the accelerated approval application with the FDA.
Phase 3 Success
Vertex reports povetacicept met primary goals in late-stage IgA nephropathy trial.
Alpine Acquisition
Vertex announces $4.9 billion acquisition of Alpine Immune Sciences to gain povetacicept.
Vertex Pharmaceuticals reported that its lead kidney drug candidate, povetacicept, achieved a 52% reduction in proteinuria in a late-stage trial for IgA nephropathy. The success validates Vertex's $4.9 billion acquisition of Alpine Immune Sciences and marks a significant step in its strategy to diversify beyond cystic fibrosis.
Source: Updated March (us) · bostonglobe.com
Alpine Immune Sciences Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
